Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Researchers from the University of Pennsylvania's Abramson Cancer Center presented preliminary results of an ongoing Phase I clinical trial demonstrating successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous CAR T therapy at the 2022 American Society of Hematology Annual Meeting.

12 Dec 2022

Whole-genome sequencing reveals five new subgroups of chronic lymphocytic leukemia

A collaborative study led by the University of Oxford as part of the UK's 100,000 Genomes Project, published in Nature Genetics today, has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukemia (CLL) and associated these with clinical outcomes.

16 Nov 2022

Better physical fitness reduces frailty risk in patients with chronic lymphocytic leukemia

Increased levels of exercise could help reduce frailty in patients with the most common form of leukemia, chronic lymphocytic (CLL), according to new research from the University of Surrey.

21 Sep 2022

How and when do de novo SARS-CoV-2 spike mutations emerge?

Researchers evaluated viral mutations in two patients with persistent SARS-CoV-2 infection.

1 Aug 2022

Novel app can help doctors make better decisions for patients with leukemia.

Researchers at the University of Copenhagen and clinicians at Rigshospitalet have developed an app that can help doctors make better decisions for patients with leukemia.

24 Jun 2022

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

In a new study, researchers evaluated the BNT162b2 coronavirus disease 2019 mRNA vaccine (antigen)-specific immune response among myeloid dysplastic syndrome and chronic lymphocytic leukemia patients.

18 May 2022

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

In a new study, researchers quantified the serological responses following the third dose of mRNA-based COVID-19 vaccines in patients with hematological malignancies.

12 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Molecular signature of highly stereotyped clonotypic anti-PF4 antibodies indicates shared pathways of antibody production in VITT patients

A recent study analyzed the antibody that mediated the COVID-19 vaccine-induced thrombotic thrombocytopenia.

7 Apr 2022

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Researchers have determined the effect of booster immunization on the levels of antibodies generated, against SARS-CoV-2 variants, including the Omicron strain, in cancer patients with or without active B cell-targeted therapy.

22 Mar 2022

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Cancer patients who have compromised immune systems due to their disease or therapy remain at high risk for COVID-19 infection.

10 Mar 2022

Defective gene in blood cancers could be treated with already available drugs

A defective gene, normally found in blood cancers, could be treated with drugs already available for cancers with similar gene defects, scientists at Queen’s University Belfast and the University of Birmingham have revealed.

13 Jan 2022

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

Researches have been investigating the possibility of using convalescent plasma to help patients recover from COVID-19.

15 Dec 2021

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

Young patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the cancer in remission.

13 Dec 2021

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.

24 Nov 2021

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Israeli researchers evaluate the antibody response in ICPs to assess antibody-mediated immunity following vaccination with the Pfizer-BioNTech vaccine.

26 Oct 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Researchers recently investigated the effect of infection with SARS-CoV-2 in patients with hematologic malignancies in minority populations.

21 Sep 2021

mRNA BNT162b2 vaccine safe in immunocompromised patients

The clinical trial showed that about 72.2% of immunocompromised patients had detectable antibodies against SARS-CoV-2.

14 Sep 2021